India, May 21 -- Hyderabad-based Bharat Biotech's Oral Cholera Vaccine Hillchol(R) has demonstrated success against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective oral cholera vaccine (OCV).

The study findings have been published in theScienceDirect, Vaccine journal 126998to assess a double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot-to-lot consistency of single component oral cholera vaccine Hillchol(R) in comparison to a comparator vaccine in a diverse participant group of 1,800 individuals, from infants to adults, across 10 clinical sites in India.

In this study, participants were divided into...